Since CHD7 is a component of the general cellular epigenetic machinery and is broadly expressed in a multitude of embryonic tissues, it could be assumed that its expression is governed by basal, proximal enhancers; however, the clinical features of CHARGE syndrome clearly suggest CHD7 has tissue and developmental stage-specific roles [3]. This evidence concerns the gene CHD7 and CHARGE syndrome.